"Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir
Human immunodeficiency virus (HIV) drugs are notorious perpetrators of drug interactions. The protease inhibitors ritonavir, indinavir, nelfinavir, saquinavir, lopinavir, and amprenavir and the reverse transcriptase inhibitor efavirenz can induce and/or inhibit the metabolism and clearance of numerous drugs (45) . Ritonavir is the most potent and efficacious inhibitor of cytochrome P4503A (CYP3A), for which it is both a substrate and a mechanism-based inhibitor (13) . Ritonavir is a standard component of highly active retroviral therapy and is included for the pharmacoenhancement of other antiretrovirals (boosting), which is achieved via greater bioavailability and increased and sustained plasma concentrations. Boosting occurs as a result of the inhibition of first-pass and hepatic CYP3A activity and/or the inhibition of P-glycoprotein activity (42) .
Although traditionally associated with cytochrome P450 (CYP) inhibition, there is growing evidence that protease inhibitors also can cause CYP induction and attendant drug interactions. Specifically, ritonavir has been shown to induce CYP2B6 mRNA, protein expression, and catalytic activity in human hepatocytes in vitro (8, 15) . Clinically, ritonavir has been shown to increase the metabolism and/or clearance of drugs such as meperidine, ethinyl estradiol, olanzapine, trimethoprim-sulfamethoxazole, and methadone (45) . Such induction might be attributable to effects on CYP2B6 activity, since this isoform has been shown to metabolize meperidine (44) and methadone (20, 31, 47, 48) . Nevertheless, the clinical effects of ritonavir on human CYP2B6 activity are unknown.
The increasing significance of CYP2B6 in human drug metabolism and disposition has been recognized recently, after initially being considered a minor isoform of relative unimportance (12, 26, 49, 54) . CYP2B6 catalyzes the bioactivation of the antineoplastic agents ifosphamide, cyclophosphamide, and tamoxifen, the metabolic inactivation of anesthetics and analgesics such as methadone, meperidine, propofol, and ketamine, the biotransformation of abused drugs such as nicotine, ecstasy, and phencyclidine, and pesticides and other environmental contaminants. Notably, CYP2B6 also catalyzes the metabolism of the antiretrovirals efavirenz and nevirapine (7, 46, 49) . The proportion of drugs metabolized by CYP2B6 has been estimated to be as high as 8% (39) .
If ritonavir is a CYP2B6 inducer, this could explain the increased elimination of several drugs. The purpose of this investigation was to test the hypothesis that ritonavir is an inducer of hepatic CYP2B6 activity in humans. Subjects were studied after both acute and steady-state ritonavir treatment, since there is some evidence that the duration of administration influences enzyme inhibition (short-term ritonavir) and induction (long-term ritonavir) (22) ; there is clear evidence that the induction of methadone clearance by ritonavir is rapid (30, 34) .
The hydroxylation of (S)-bupropion was used as the in vivo probe for CYP2B6 activity, since this has been shown to be an improved CYP2B6 probe compared to racemic bupropion (32) . Although racemic bupropion clearance or hydroxylation has been used clinically to phenotype CYP2B6 activity (35, 36, 41, 50) , racemic bupropion suffers from well-documented limitations. Specifically, bupropion clearance may not reflect altered CYP2B6 activity, because hydroxylation is a minor metabolic pathway and there are alternate non-CYP2B6 routes of bupropion metabolism; also, plasma hydroxybupropion concentrations are elimination rate limited (the metabolite halflife exceeds that of the parent) rather than formation rate limited (36, 50) . Both (R)-and (S)-bupropion were hydroxylated by CYP2B6, but the metabolism was stereoselective (4), and clinically, the apparent oral clearance (CL/F) of (S)-bupropion was threefold greater than that of (R)-and (R,S)-bupropion (32) . More importantly, (S,S)-hydroxybupropion was formation rate limited, while (R,R)-hydroxybupropion and (R,R),(S,S)-hydroxybupropion were elimination rate limited; hence, (S,S)-hydroxybupropion formation is a better in vivo CYP2B6 probe (32) .
MATERIALS AND METHODS
Study population and protocol. Thirteen volunteers (four males, nine females) participated in the investigation, which was approved by the Washington University Institutional Review Board, after written informed consent was obtained. Inclusion criteria included being (i) 18 to 40 years old and (ii) within 30% of ideal body weight. Exclusion criteria were (i) major medical problems; (ii) a history of liver or renal disease; (iii) the use of prescription medications, drugs, herbals, and foods metabolized by or altering CYP2B6 or CYP3A4; and (iv) a family history of type 2 diabetes. Females taking hormonal contraceptives were excluded from enrollment. Both smokers and nonsmokers were enrolled. Subjects underwent a screening visit, during which blood samples for fasting glucose concentration and HIV serologic status were obtained. Subjects were excluded if their glucose exceeded 110 mg/dl (because ritonavir can cause glucose intolerance) or if they were HIV seropositive (since monotherapy can cause HIV resistance). The final study population was comprised of 13 subjects (29 Ϯ 5 years [range, 23 to 39 years], 67 Ϯ 9 kg [range, 53 to 84 kg]). One additional subject completed the control session but withdrew after starting ritonavir due to nausea, fatigue, and cramping, and the control session data are not included in the data set.
The protocol used a three-session sequential crossover design (with the control session first due to logistical considerations). There was at least a 2-week washout between the first two study sessions. Subjects were instructed to consume no orange-, apple-, or grapefruit-containing foods or juices for 5 days before and on each study day and no alcohol or caffeine for 24 h before and on each study day. An intravenous catheter was placed in an arm vein for blood sampling. Subjects received 150 mg oral immediate-release bupropion on three occasions after no pretreatment (control), on the 3rd day of ritonavir treatment, and on the 17th day of ritonavir treatment. Ritonavir dosing was 200 mg three times daily for 1 day, 300 mg twice daily for the next 6 days, and then 400 mg twice daily. The last ritonavir dose was taken the night before the last blood sample, and the total duration of administration was 18 days. Previous investigations suggested that steady-state induction is achieved after approximately 2 weeks of ritonavir (28, 40, 43) . Venous blood samples were obtained for 48 h after bupropion treatment, and plasma was separated and stored at Ϫ20°C for later analysis. All urine was collected for 48 h after bupropion treatment as two 24-h collections, the volume was measured, and an aliquot was stored at Ϫ20°C for later analysis. Subjects were fed a light breakfast 3 h after bupropion administration and had free access to food and water thereafter.
Analytical methods. Plasma and urine (R)-and (S)-bupropion and (R,R)-and (S,S)-hydroxybupropion concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry as described previously (3) . Interday coefficients of variation were the following: for 1, 10, and 100 ng/ml (R)-bupropion, 9, 9, and 8%, respectively; for 1, 10, and 100 ng/ml (S)-bupropion, 10, 9, and 10%, respectively; for 5, 50, and 500 ng/ml (R,R)-hydroxybupropion, 10, 5, and 8%, respectively; and for 5, 50, and 500 ng/ml (S,S)-hydroxybupropion, 8, 6 , and 3%, respectively. Pharmacokinetic analysis. Data were analyzed using noncompartmental methods (WinNonlin 5.1; Pharsight Corp., Mountain View, CA) as described previously (33) . The CL/F was the ratio of the dose to the area under the concentration-time curve (AUC), and the apparent renal or formation clearance was calculated as the product of the fraction of the dose recovered in urine and CL/F. Sample size. For statistical power calculations, we consider a simplified analysis (paired t test) for comparing control and HIV drug treatments that was based on the primary outcome variable: the plasma hydroxybupropion/bupropion AUC ratio. Intraindividual variability in this parameter has not been determined; hence, it could not be used for sample size calculation. Nevertheless, experience with within-subject (interday) variability in the clearance of other P450 probes suggested that the intraindividual coefficients of variation typically were 30 to 40%. For a primary outcome variable, detecting a 30% change (standard deviation [SD], 35%; ␣, 0.05; ␤, 0.8) would require 13 subjects. Furthermore, previous induction studies using 12 subjects were adequately powered to detect induction (30) .
Statistical analysis. Results are expressed as the means Ϯ SD or median. Analysis of variance was used to assess the significance of differences between treatments (SigmaStat 3.5; Systat Corp). Nonnormal data were log transformed for statistical analysis. Significance was assigned at P Ͻ 0.05. Differences between treatments in clearances and AUC ratios also were assessed as the geometric mean ratios (ritonavir/control) and the 90% confidence intervals of the geometric means. Confidence intervals excluding unity were considered statistically significant.
RESULTS
One subject withdrew (for scheduling reasons) during the steady-state ritonavir phase of the protocol; thus, data were not obtained for this subject session. Results are presented for 13 subjects (control and 3 days of ritonavir) and for 12 subjects (2.5 weeks of ritonavir).
Ritonavir caused significant changes in bupropion disposition. Plasma concentrations of both (R)-and (S)-bupropion were diminished after both 3 days of ritonavir treatment and steady-state ritonavir treatment (Fig. 1) . The ratios of plasma AUC from 0 h to infinity (AUC 0-ϱ ) (ritonavir/control) for racemic, (R)-, and (S)-bupropion were significantly reduced to 0.84, 0.86, and 0.80, respectively, after 3 days of ritonavir treatment and to 0.67, 0.69, and 0.60 after more than 2 weeks of ritonavir treatment (Table 1) . (R)-, (S)-, and racemic bupropion CL/Fs all were significantly increased by 1.2-fold after 3 days of ritonavir treatment and by 1.4-, 1.7, and 1.5-fold after steady-state ritonavir treatment. Short-term ritonavir decreased the plasma AUC 0-ϱ of total and (R,R)-hydroxybupropion but not (S,S)-hydroxybupropion, while steady-state ritonavir treatment decreased the plasma AUC 0-ϱ of total, (R,R)-, and (S,S)-hydroxybupropion (Fig. 2) . The median apparent elimination half-life of total, (R,R)-, and (S,S)-hydroxybupropion was reduced from 32, 33, and 18 h, respectively, to 17, 18, and 13 h by 3 days of ritonavir treatment and to 11 h for all three by steady-state ritonavir treatment. The plasma hydroxybupropion/bupropion AUC 0-48 ratios for racemic and (R)-bupropion were minimally changed or were unchanged by both short-term and steady-state ritonavir treatments, while the metabolite/parent ratio for (S)-bupropion was increased by both short-term and steady-state ritonavir treatments. Ritonavir caused a 1.8-fold increase in the formation clearance of both (R,R)-and (S,S)-hydroxybupropion after 3 days and a 2.1-fold increase after 2 weeks (Table 2) . Similar results were observed for the 0-to 24-h urine hydroxybupropion/bupropion molar ratio. Ritonavir had no effect on bupropion enantiomer renal clearance.
DISCUSSION
This investigation demonstrates that short-term (3 days) and steady-state ritonavir treatments significantly increased (S)-bupropion hydroxylation. Specifically, ritonavir increased (S,S)-hydroxybupropion apparent formation clearance, 0-to 24-h urine (S,S)-hydroxybupropion/(S)-bupropion molar ratios, plasma (S,S)-hydroxybupropion/(S)-bupropion AUC ratios, and (S)-bupropion CL/F. Changes in (S)-bupropion clearance were not due to increased bupropion renal clearance. (S)-Bupropion hydroxylation is catalyzed selectively by CYP2B6 and an in vivo probe for CYP2B6 (32) . Therefore, these results strongly support the conclusion that human hepatic CYP2B6 activity in vivo is induced by both short-term and steady-state ritonavir treatments, with the latter causing an approximately twofold increase. Although ritonavir also increased apparent formation clearances, urine hydroxybupropion/bupropion molar ratios, and systemic clearance of (R,R)-and racemic hydroxybupropion, plasma hydroxybupropion/ bupropion AUC ratios were decreased rather than increased. There is insufficient understanding of hydroxybupropion elimination to explain this last observation (32) .
One previous investigation evaluated the effects of ritonavir on bupropion disposition (24) . Subjects received bupropion (presumably the immediate-release variety, although it was not specified) on the second day of treatment with 200 mg ritonavir twice daily. Racemic bupropion and metabolite plasma concentrations were measured for 24 h. Neither bupropion nor hydroxybupropion concentrations were significantly altered by ritonavir, and the hydroxybupropion/bupropion ratio was insignificantly decreased by 15%, which was interpreted as suggesting no effect on CYP2B6 activity. There are, however, differences between previous studies and the present study. Hesse et al. evaluated racemic bupropion plasma concentrations and the hydroxybupropion/bupropion AUC ratio (24) . Nevertheless, plasma bupropion concentrations may be insensitive to altered CYP2B6 activity, because CYP2B6-catalyzed hydroxylation is only a minor route of overall bupropion elimination (36, 50) . Additionally, the plasma hydroxybupropion/ bupropion AUC ratio may be confounded, because racemic hydroxybupropion is elimination rate rather than formation rate limited, and hydroxybupropion elimination also may be altered (32, 36) . Hesse et al. also evaluated bupropion metabolism after fewer and lower doses of ritonavir (three to four doses of 200 mg) than those used herein (3 days of two doses of 200 mg and three to four doses of 300 mg and 2.5 weeks of 400 mg twice daily) and speculated that longer ritonavir exposure might induce CYP2B6. The present investigation demonstrates that both short-term and steady-state ritonavir treatments do induce hepatic CYP2B6 activity.
The ritonavir induction of hepatic CYP2B6 is consistent with previous in vitro findings. Ritonavir increased CYP2B6 mRNA expression in LS180 adenocarcinoma cells (23) and induced CYP2B6 mRNA expression, immunoreactive protein expression, and catalytic activity in primary human hepatocytes (8, 15) . Ritonavir was classified as a strong in vitro CYP2B6 inducer, along with rifampin, phenobarbital, phenytoin, and clotrimazole (15) .
Other CYP2B6 inducers also have been shown to induce the metabolism of racemic bupropion and other CYP2B6 substrates. The prototypic CYP2B6 inducer rifampin induced bupropion clearance by threefold and increased peak plasma hydroxybupropion concentrations (36) . Lopinavir/ritonavir (400 mg lopinavir/100 mg ritonavir twice daily for 2 weeks) decreased the plasma AUC for bupropion and hydroxybupropion by 57 and 50%, respectively (27) . Ritonavir (500 mg twice daily for 10 days) decreased the plasma meperidine AUC and increased the normeperidine AUC, suggesting the induction of metabolism (43) . Although this was initially attributed to CYP3A induction (43) , subsequent reports showing that meperidine is primarily a CYP2B6 substrate (44) and that ritonavir does not induce CYP3A4 (see below) suggest that the ritonavir enhancement of meperidine metabolism and clearance likely reflects CYP2B6 induction.
The ritonavir induction of hepatic CYP2B6 activity has clin-
FIG. 1. Plasma concentrations of racemic bupropion (A) and bupropion enantiomers (B and C).
Results are the means Ϯ SD (n ϭ 13 for controls and acute ritonavir treatment; n ϭ 12 for steady-state ritonavir treatment). Some SD are omitted for clarity. (30, 34) . This occurred despite the profound ritonavir inhibition of CYP3A. The mechanism by which ritonavir induces methadone clearance is unknown. Methadone metabolism and clearance in vivo traditionally have been attributed to CYP3A (5, 10, 18) and ritonavir effects on methadone disposition to CYP3A induction (19, 38) . Notwithstanding years of the clinical use of these drugs, the paradox of the ritonavir induction of methadone clearance despite CYP3A inhibition remains unexplained. Recent evidence suggests a a Subjects received 150 mg oral immediate-release racemic bupropion alone on the 3rd day of ritonavir (300 mg twice daily) treatment or on the 17th day of ritonavir (400 mg twice daily) treatment.
b C max , maximum concentration of drug in plasma; T max , time to maximum concentration of drug in plasma; t 1/2 , elimination half-life. c Parameter ratios (ritonavir/control) are the geometric means and the 90% confidence intervals about the geometric means (in parentheses). An asterisk indicates a value that is different from that for the control (P Ͻ 0.05).
significant, if not predominant, role for CYP2B6 in methadone metabolism and clearance (20, 31, 47, 48) . CYP3A inhibition failed to diminish methadone metabolism and clearance (30, 31, 34) . Conversely, rifampin, which induces CYP2B6, increased methadone metabolism and clearance at a level similar to that by ritonavir. This suggests that the ritonavir induction of methadone metabolism and clearance may be mediated by hepatic CYP2B6 induction.
The clinical effects of ritonavir on human hepatic CYP2B6 are diametrically opposite to those on hepatic and intestinal CYP3A. Ritonavir is one of the most potent and efficacious mechanism-based inhibitors of CYP3A isoforms in vitro (13) .
Clinically, acute and steady-state ritonavir treatments profoundly inhibit first-pass and hepatic CYP3A. Several recent investigations, using well-characterized CYP3A probes such as midazolam, triazolam, and alfentanil, demonstrated Ͼ95% inhibition of first-pass CYP3A activity by various ritonavir regimens, such as 100 to 200 mg/day, 200 mg twice daily, and 400 mg twice daily (6, 17, 22, 30, 34) . Although early clinical investigations suggested that steady-state ritonavir treatment induced CYP3A based on the autoinduction of ritonavir clearance (29) and decreased ethinyl estradiol AUC and half-life (40) , nevertheless it was recognized that such effects also could emanate from ritonavir induction of efflux transporters (6).
FIG. 2. Plasma concentrations of racemic hydroxybupropion (A) and hydroxybupropion diastereomers (B and C).
Results are the means Ϯ SD (n ϭ 13 for controls and acute ritonavir treatment; n ϭ 12 for steady-state ritonavir treatment). Some SDs are omitted for clarity. Acute ritonavir (n ϭ 13) Steady-state ritonavir (n ϭ 12)
The contradictory effects of ritonavir on human hepatic CYP2B6 and CYP3A activities are paradoxical, particularly since these isoforms share common regulatory pathways. The orphan nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) both regulate the expression of CYP2B and CYP3A (51) . Early investigations suggested that PXR and CAR were the predominant activators of CYP3A and CYP2B, respectively, although later findings of cross-talk between PXR and CAR demonstrated the reciprocal activation of their response elements (52) . Cross-talk is asymmetrical, so that the activation of human PXR, which has a large and accommodating active site that binds numerous and diverse ligands (2, 11) , results in the nonselective activation of both CYP2B6 and CYP3A4 (14) . Conversely, human CAR, which has a smaller binding site (53), preferentially activates CYP2B6 over CYP3A4 (14) . A recent screen of CYP2B6 and/or CYP3A4 inducers identified three classes: selective human PXR activators (i.e., rifampin), mixed human PXR and CAR activators (i.e., troglitazone), and preferential human CAR activators (i.e., efavirenz and nevirapine) (16) . One possible explanation for reciprocal CYP2B6 induction/ CYP3A inhibition by ritonavir is PXR activation combined with mechanism-based CYP3A inhibition. In human hepatocytes, ritonavir strongly activated PXR, upregulated CYP2B6 and CYP3A mRNA levels, and induced both CYP3A and CYP2B6 protein expression (8, 9, 15, 23, 37) . Ritonavir was the most potent and efficacious PXR activator (15, 23) , although it was not as efficacious in inducing CYP3A4 as predicted by PXR activation (23, 37) . More importantly, while ritonavir induced both CYP2B6 and CYP3A4 protein expression, CYP3A activity was completely inhibited (8, 15, 37) . Thus, the PXR-mediated coordinate upregulation of CYP2B6 and CYP3A4 expression by ritonavir was offset by the selective inhibition of CYP3A4 and not CYP2B6. Ritonavir is a potent (K i Ͻ 0.1 M) mechanism-based CYP3A4 inhibitor (13, 21 ). It appears to be a less potent inhibitor of CYP2B6 (50% inhibitory concentration, 2 M) (25) . A similar in vivo scenario could result in the upregulation of both CYP3A4 and CYP2B6 expression, with the selective inhibition of CYP3A4 activity. Another possible explanation for the reciprocal clinical ritonavir induction of CYP2B6 and inhibition of CYP3A is that ritonavir is a preferential human CAR activator, resulting in selective CYP2B6 upregulation and likely also CYP3A4 inhibition. The antiretrovirals efavirenz and nevirapine have been characterized as preferential human CAR activators (16); however, the effects of ritonavir on CAR have not been reported.
One potential limitation of this investigation is that the steady-state ritonavir dose differs from that used in typical contemporary antiretroviral regimens (42) . In early clinical use, ritonavir was dosed at 600 mg twice daily, although this dose was associated with considerable drug interactions and generally is no longer used for treating HIV-infected patients. Contemporary use is predominately in lower doses, typically 100 to 200 mg once or twice daily. The present protocol was designed as a mechanistic investigation specifically to provide insights into the mechanism of the ritonavir induction of methadone clearance in our previous investigation using the same dose of 400 mg twice daily (30, 34) . Nonetheless, CYP2B6 induction occurred at higher (400 mg twice daily) as well as lower doses (after only 2 days of 200 to 300 mg twice daily) and also after longer periods at 100 mg twice daily (27) . Thus, the present investigation has both mechanistic and clinical relevance to ritonavir use at lower doses.
Ritonavir prescribing guidelines suggest that concomitant use with bupropion increases, or is predicted to increase, bupropion concentrations. Caution is advised if bupropion is administered with ritonavir, with a dosage reduction potentially being necessary (Norvir [ritonavir] soft gelatin capsules and oral solution prescribing information, Abbott Laboratories, North Chicago, IL). This may be based in part on extrapolation from the in vitro ritonavir inhibition of human liver microsomal bupropion hydroxylation (25) . The present study demonstrates the need for caution in extrapolating in vitro observations and the necessity of performing clinical investigations to verify such observations, and it suggests that a revision of the ritonavir dosing guidelines is appropriate.
In summary, the present investigation shows that short-term (2 to 3 days) and steady-state ritonavir treatments increase the hydroxylation and clearance of the CYP2B6 probe (S)-bupropion, suggesting that ritonavir induces human CYP2B6 activity. CYP2B6 induction occurs despite the profound inhibition of CYP3A4 activity.
